Meta Board Shakeup Raises Scrutiny, Governance Changes Amid AI Push

Dina Powell McCormick departed Meta's board effective December 19 to December 20, 2025, according to recent Securities and Exchange Commission filings. The timing coincided with a high stakes resolution in Delaware Chancery Court and a newly announced joint venture between Meta and Reliance Industries to invest ₹855 crore in artificial intelligence services in India. Together these developments underscore growing pressure on technology companies to reconcile rapid AI deployment with strengthened governance and accountability.

Meta reached a derivative settlement in Delaware that has been described as among the largest derivative recoveries in the court's history. The accord requires the company to adopt governance reforms meant to bolster privacy oversight and enhance protections for employees who raise concerns. As part of related litigation over the Cambridge Analytica scandal, Mark Zuckerberg and other Meta directors agreed to a $190 million payment to settle a shareholder lawsuit. That payment will be made through directors and officers insurance rather than from executives' personal funds. Plaintiffs' lawyers have signaled they will seek fees of up to 30 percent of the settlement plus expenses, to be paid from the settlement proceeds. Pension funds and institutional investors who led the derivative suit framed the settlement as a step toward greater board accountability.

At the same time, Meta and Reliance Industries have formed a joint venture to develop and distribute AI services in India, committing ₹855 crore to the initiative. The move illustrates how companies are pursuing international markets and commercial AI opportunities even as they confront intensified legal and oversight demands at home. The simultaneous pursuit of aggressive AI expansion and remedial governance measures presents a paradox for corporate leaders, regulators, and investors.

The public health implications are significant. As technology platforms expand AI capabilities into new markets, the stewardship of personal data becomes a public health concern. AI systems trained on or integrated with health related data can influence access to care, the accuracy of clinical decision support, and the targeting of public health messaging. Weak oversight or insufficient whistleblower protections can allow privacy risks and biased systems to persist, disproportionately harming low income communities and historically marginalized groups who already face barriers to health care and digital inclusion.

Policy makers and health advocates are likely to watch how the mandated governance reforms are implemented, and whether board level expertise and independent oversight are strengthened in practice. The reliance on directors and officers insurance to satisfy large settlements raises questions about deterrence and personal accountability for failures that put users and communities at risk. For employees, enhanced whistleblower protections may encourage reporting of unsafe practices, but the effectiveness of such protections will depend on clear procedures, protections from retaliation, and timely enforcement.

Several specifics remain unclear. The filings did not explain the reason for McCormick's resignation, the detailed timeline for implementing the court ordered governance reforms was not disclosed, and the operational structure and product roadmap for the India joint venture were not detailed publicly. What is clear is that the episode highlights a sector wide moment: investors, courts, and governments are demanding stronger governance even as companies move quickly to commercialize AI, with real consequences for privacy, health equity, and public trust.